Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Common Equity came in at $443.2 million in Q1 2026, down 31.55% YoY from $647.4 million in Q1 2025, and down 12.87% on a QoQ basis from $508.6 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Common Equity (2019 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 8 years of Common Equity data on file, last reported at $443.2 million in Q1 2026.
- Quarterly Common Equity fell 31.55% year-over-year to $443.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $443.2 million (down 31.55% YoY) and the FY2025 annual result came in at $508.6 million, down 28.97% from the prior year.
- Common Equity declined to $443.2 million in Q1 2026, from $508.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.7 billion in Q4 2022 to a low of $443.2 million in Q1 2026.
- A 5-year average of $1.1 billion and a median of $987.3 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2022 — Common Equity jumped 341.91% — and 2024, when it sank 44.59%.
- Tracing DNA's Common Equity over 5 years: stood at $1.7 billion in 2022, then tumbled by 36.81% to $1.1 billion in 2023, then sank by 34.73% to $716.1 million in 2024, then retreated by 28.97% to $508.6 million in 2025, then slipped by 12.87% to $443.2 million in 2026.
- The last three Common Equity figures came in at $443.2 million (Q1 2026), $508.6 million (Q4 2025), and $559.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 420.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 420.28 Mn |
| Mar 31, 2026 | 443.15 Mn |
| Dec 31, 2025 | 508.59 Mn |
| Sep 30, 2025 | 559.78 Mn |
| Jun 30, 2025 | 612.95 Mn |
| Mar 31, 2025 | 647.43 Mn |
| Dec 31, 2024 | 716.06 Mn |
| Sep 30, 2024 | 797.94 Mn |
| Jun 30, 2024 | 833.07 Mn |
| Mar 31, 2024 | 987.27 Mn |
| Dec 31, 2023 | 1.10 Bn |
| Sep 30, 2023 | 1.25 Bn |
| Jun 30, 2023 | 1.50 Bn |
| Mar 31, 2023 | 1.61 Bn |
| Dec 31, 2022 | 1.74 Bn |
| Sep 30, 2022 | 1.44 Bn |
| Jun 30, 2022 | 1.57 Bn |
| Mar 31, 2022 | 1.62 Bn |
| Dec 31, 2021 | 1.57 Bn |
| Sep 30, 2021 | 1.62 Bn |